Robert G. Kramer sold nearly 90,000 shares of his stock in Emergent BioSolutions, knowing that large quantities of vaccine materials were contaminated, the lawsuit said.
Letitia James accused Robert Kramer of selling his shares in Emergent before disclosing contamination issues in its production of the Covid-19 vaccine.
Daily Voice on MSN
NY AG sues former Emergent CEO over insider trading
A former biotech CEO pocketed more than $10 million by selling company stock after learning of serious COVID-19 vaccine contamination problems — before those issues were made public, according to a ...
NEW YORK – A former chief executive of Gaithersburg-based Emergent BioSolutions was charged on Thursday with insider trading by New York Attorney General Letitia James for allegedly selling the ...
Emergent BioSolutions Inc. (NYSE: EBS) stock rose in Friday premarket trading. On Thursday, New York Attorney General Letitia James sued former chief executive Robert G. Kramer over alleged insider ...
Two years ago, Emergent BioSolutions came to a settlement with shareholders, agreeing to pay $40 million to resolve allegations of wrongdoing by company executives, which included insider trading ...
On January 15, 2026, the New York Attorney General (“NYAG”) filed a complaint against a former life-sciences manufacturing CEO alleging violations ...
Plus: Nine displaced during Chevy Chase townhouse fire; Tato’s potato bar to open in Westfield Montgomery mall ...
New York Attorney General Letitia James filed suit against the former head of Emergent BioSolutions, accusing him of insider trading for selling his shares in the company before disclosing ...
New York Attorney General Letitia James filed suit against the former head of Emergent BioSolutions, accusing him of insider trading for selling his shares in the company before disclosing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results